<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36614118</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Effect of Rapamycin on TDP-43-Related Pathogenesis in Ischemic Stroke.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">676</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24010676</ELocationID><Abstract><AbstractText>Stroke is a major cause of death and disability across the world, and its detrimental impact should not be underestimated. Therapies are available and effective for ischemic stroke (e.g., thrombolytic recanalization and mechanical thrombectomy); however, there are limitations to therapeutic interventions. Recanalization therapy has developed dramatically, while the use of adjunct neuroprotective agents as complementary therapies remains deficient. Pathological TAR DNA-binding protein (TDP-43) has been identified as a major component of insoluble aggregates in numerous neurodegenerative pathologies, including ALS, FTLD and Alzheimer's disease. Here, we show that increased pathological TDP-43 fractions accompanied by impaired mitochondrial function and increased gliosis were observed in an ischemic stroke rat model, suggesting a pathological role of TDP-43 in ischemic stroke. In ischemic rats administered rapamycin, the insoluble TDP-43 fraction was significantly decreased in the ischemic cortex region, accompanied by a recovery of mitochondrial function, the attenuation of cellular apoptosis, a reduction in infarct areas and improvements in motor defects. Accordingly, our results suggest that rapamycin provides neuroprotective benefits not only by ameliorating pathological TDP-43 levels, but also by reversing mitochondrial function and attenuating cell apoptosis in ischemic stroke.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsou</LastName><ForeName>Yi-Syue</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Taipei Medical University Hospital, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taipei Neuroscience Institute, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Jing-Huei</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-2894-9325</Identifier><AffiliationInfo><Affiliation>Core Laboratory of Neuroscience, Office of R&amp;D, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurotrauma and Neuroregeneration, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kai-Yun</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Cheng-Fu</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0002-3416-261X</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, Taipei City Hospital, Zhong Xiao Branch, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chi-Chen</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-5410-8285</Identifier><AffiliationInfo><Affiliation>Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST 110-2320-B-038 -067 -MY3.</GrantID><Agency>Ministry of Science and Technology</Agency><Country/></Grant><Grant><GrantID>108TMU-SSH-13</GrantID><Agency>Taipei Medical University Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000083242" MajorTopicYN="Y">Ischemic Stroke</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">ischemic stroke</Keyword><Keyword MajorTopicYN="N">rapamycin</Keyword></KeywordList><CoiStatement>The authors declare that no conflict of interest exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>8</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36614118</ArticleId><ArticleId IdType="pmc">PMC9820757</ArticleId><ArticleId IdType="doi">10.3390/ijms24010676</ArticleId><ArticleId IdType="pii">ijms24010676</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Virani S.S., Alvaro A., Benjamin E., Bittencourt M., Callaway C., Carson A., Chamberlain A., Chang A., Cheng S., Delling F., et al. Heart disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139&#x2013;e596. doi: 10.1161/CIR.0000000000000757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000757</ArticleId><ArticleId IdType="pubmed">31992061</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mufti F., Amuluru K., Roth W., Nuoman R., El-Ghanem M., Meyers P.M. Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions. Neurosurgery. 2018;82:781&#x2013;789. doi: 10.1093/neuros/nyx341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuros/nyx341</ArticleId><ArticleId IdType="pubmed">28973661</ArticleId></ArticleIdList></Reference><Reference><Citation>Pac-Soo C.K., Mathew H., Ma D. Ischaemic conditioning strategies reduce ischaemia/reperfusion-induced organ injury. Br. J. Anaesth. 2015;114:204&#x2013;216. doi: 10.1093/bja/aeu302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeu302</ArticleId><ArticleId IdType="pubmed">25216929</ArticleId></ArticleIdList></Reference><Reference><Citation>Nour M., Scalzo F., Liebeskind D.S. Ischemia-reperfusion injury in stroke. Interv. Neurol. 2013;1:185&#x2013;199. doi: 10.1159/000353125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000353125</ArticleId><ArticleId IdType="pmc">PMC4031777</ArticleId><ArticleId IdType="pubmed">25187778</ArticleId></ArticleIdList></Reference><Reference><Citation>White B.C., Sullivan J.M., DeGracia D.J., O&#x2019;Neil B.J., Neumar R.W., Grossman L.I., Rafols J.A., Krause G.S. Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury. J. Neurol. Sci. 2000;179:1&#x2013;33. doi: 10.1016/S0022-510X(00)00386-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(00)00386-5</ArticleId><ArticleId IdType="pubmed">11054482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugawara T., Chan P.H. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antioxid. Redox Signal. 2003;5:597&#x2013;607. doi: 10.1089/152308603770310266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/152308603770310266</ArticleId><ArticleId IdType="pubmed">14580316</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger D.N., Kvietys P.R. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol. 2015;6:524&#x2013;551. doi: 10.1016/j.redox.2015.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2015.08.020</ArticleId><ArticleId IdType="pmc">PMC4625011</ArticleId><ArticleId IdType="pubmed">26484802</ArticleId></ArticleIdList></Reference><Reference><Citation>Janardhan V., Qureshi A.I. Mechanisms of ischemic brain injury. Curr. Cardiol. Rep. 2004;6:117&#x2013;123. doi: 10.1007/s11886-004-0009-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-004-0009-8</ArticleId><ArticleId IdType="pubmed">14759356</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., Pantano S., D'Ambrogio A., Buratti E., Brindisi A., Marchetti C., Romano M., Baralle F.E. Human, Drosophila, and C. elegans TDP43: Nucleic acid binding properties and splicing regulatory function. J. Mol. Biol. 2005;348:575&#x2013;588. doi: 10.1016/j.jmb.2005.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.02.038</ArticleId><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F.E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem. 2001;276:36337&#x2013;36343. doi: 10.1074/jbc.M104236200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104236200</ArticleId><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y., Urushitani M. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD. Int. J. Mol. Sci. 2022;23:12508. doi: 10.3390/ijms232012508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232012508</ArticleId><ArticleId IdType="pmc">PMC9604209</ArticleId><ArticleId IdType="pubmed">36293362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M., Zhang H., Kai J., Zhu F., Dong J., Xu Z., Wong M., Zeng L.H. Rapamycin prevents cerebral stroke by modulating apoptosis and autophagy in penumbra in rats. Ann. Clin. Transl. Neurol. 2018;5:138&#x2013;146. doi: 10.1002/acn3.507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.507</ArticleId><ArticleId IdType="pmc">PMC5817831</ArticleId><ArticleId IdType="pubmed">29468175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons J.J., Abraham R.T., Yu K. Mammalian target of rapamycin: Discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 2009;36((Suppl. 3)):S3&#x2013;S17. doi: 10.1053/j.seminoncol.2009.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2009.10.011</ArticleId><ArticleId IdType="pubmed">19963098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou L.M., Lin R.Z. Rapamycin and mTOR kinase inhibitors. J. Chem. Biol. 2008;1:27&#x2013;36. doi: 10.1007/s12154-008-0003-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12154-008-0003-5</ArticleId><ArticleId IdType="pmc">PMC2698317</ArticleId><ArticleId IdType="pubmed">19568796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove J., Martinez-Vicente M., Vila M. Fighting neurodegeneration with rapamycin: Mechanistic insights. Nat. Rev. Neurosci. 2011;12:437&#x2013;452. doi: 10.1038/nrn3068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3068</ArticleId><ArticleId IdType="pubmed">21772323</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang I.F., Guo B.S., Liu Y.C., Wu C.C., Yang C.H., Tsai K.J., Shen C.K. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc. Natl. Acad. Sci. USA. 2012;109:15024&#x2013;15029. doi: 10.1073/pnas.1206362109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206362109</ArticleId><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Goossens J., Vanmechelen E., Trojanowski J.Q., Lee V.M., Van Broeckhoven C., van der Zee J., Engelborghs S. TDP-43 as a possible biomarker for frontotemporal lobar degeneration: A systematic review of existing antibodies. Acta Neuropathol. Commun. 2015;3:15. doi: 10.1186/s40478-015-0195-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0195-1</ArticleId><ArticleId IdType="pmc">PMC4380254</ArticleId><ArticleId IdType="pubmed">25853864</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T.G., Buratti E., Baralle F., Morita M., et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y., Li S., Chen S., Sun X., Yang F., Wang H., Li M., Cui F., Huang X. TDP-43 and Phosphorylated TDP-43 Levels in Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis. Front. Neurol. 2021;12:663637. doi: 10.3389/fneur.2021.663637.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.663637</ArticleId><ArticleId IdType="pmc">PMC8236522</ArticleId><ArticleId IdType="pubmed">34194383</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn J.M., Melov S. SOD2 in mitochondrial dysfunction and neurodegeneration. Free Radic. Biol. Med. 2013;62:4&#x2013;12. doi: 10.1016/j.freeradbiomed.2013.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.05.027</ArticleId><ArticleId IdType="pmc">PMC3811078</ArticleId><ArticleId IdType="pubmed">23727323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozaki Y., Nakata Y., Kameoka M., Hayashi N., Nakayama Y., Yagi K. Clinical analysis of 104 cases of overdose in suicide attempts. Chudoku Kenkyu. 2007;20:367&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">18044219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang I., Chu C.T., Kaufman B.A. The mitochondrial transcription factor TFAM in neurodegeneration: Emerging evidence and mechanisms. FEBS Lett. 2018;592:793&#x2013;811. doi: 10.1002/1873-3468.12989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12989</ArticleId><ArticleId IdType="pmc">PMC5851836</ArticleId><ArticleId IdType="pubmed">29364506</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto N., Miyazaki K., Kurata T., Ikeda Y., Matsuura T., Kang D., Ide T., Abe K. Effect of mitochondrial transcription factor a overexpression on motor neurons in amyotrophic lateral sclerosis model mice. J. Neurosci. Res. 2012;90:1200&#x2013;1208. doi: 10.1002/jnr.23000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23000</ArticleId><ArticleId IdType="pubmed">22354563</ArticleId></ArticleIdList></Reference><Reference><Citation>Spronk E., Sykes G., Falcione S., Munsterman D., Joy T., Kamtchum-Tatuene J., Jickling G.C. Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation. Front. Neurol. 2021;12:661955. doi: 10.3389/fneur.2021.661955.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.661955</ArticleId><ArticleId IdType="pmc">PMC8160112</ArticleId><ArticleId IdType="pubmed">34054705</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado B., Melo L., Pinto R., Lobo A., Barros P., Gomes J.R. Ischemic Stroke, Lessons from the Past towards Effective Preclinical Models. Biomedicines. 2022;10:2561. doi: 10.3390/biomedicines10102561.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10102561</ArticleId><ArticleId IdType="pmc">PMC9599148</ArticleId><ArticleId IdType="pubmed">36289822</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Zoppo G.J., Saver J.L., Jauch E.C., Adams H.P., Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945&#x2013;2948. doi: 10.1161/STROKEAHA.109.192535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.109.192535</ArticleId><ArticleId IdType="pmc">PMC2782817</ArticleId><ArticleId IdType="pubmed">19478221</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyerly M.J., Albright K.C., Boehme A.K., Shahripour R.B., Houston J.T., Rawal P.V., Kapoor N., Alvi M., Sisson A., Alexandrov A.W., et al. The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat? J. Neurol. Disord. Stroke. 2013;1:1015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901990</ArticleId><ArticleId IdType="pubmed">24471140</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkhemer O.A., Fransen P.S., Beumer D., van den Berg L.A., Lingsma H.F., Yoo A.J., Schonewille W.J., Vos J.A., Nederkoorn P.J., Wermer M.J., et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 2015;372:11&#x2013;20. doi: 10.1056/NEJMoa1411587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1411587</ArticleId><ArticleId IdType="pubmed">25517348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracard S., Ducrocq X., Mas J.L., Soudant M., Oppenheim C., Moulin T., Guillemin F. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): A randomised controlled trial. Lancet Neurol. 2016;15:1138&#x2013;1147. doi: 10.1016/S1474-4422(16)30177-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30177-6</ArticleId><ArticleId IdType="pubmed">27567239</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell B.C., Mitchell P.J., Kleinig T.J., Dewey H.M., Churilov L., Yassi N., Yan B., Dowling R.J., Parsons M.W., Oxley T.J., et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 2015;372:1009&#x2013;1018. doi: 10.1056/NEJMoa1414792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414792</ArticleId><ArticleId IdType="pubmed">25671797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocco J., Zaidat O.O., von Kummer R., Yoo A.J., Gupta R., Lopes D., Frei D., Shownkeen H., Budzik R., Ajani Z.A., et al. Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone. Stroke. 2016;47:2331&#x2013;2338. doi: 10.1161/STROKEAHA.116.013372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.116.013372</ArticleId><ArticleId IdType="pubmed">27486173</ArticleId></ArticleIdList></Reference><Reference><Citation>Saver J.L., Goyal M., Bonafe A., Diener H.C., Levy E.I., Pereira V.M., Albers G.W., Cognard C., Cohen D.J., Hacke W., et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N. Engl. J. Med. 2015;372:2285&#x2013;2295. doi: 10.1056/NEJMoa1415061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1415061</ArticleId><ArticleId IdType="pubmed">25882376</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovin T.G., Chamorro A., Cobo E., de Miquel M.A., Molina C.A., Rovira A., San Rom&#xe1;n L., Serena J., Abilleira S., Rib&#xf3; M., et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N. Engl. J. Med. 2015;372:2296&#x2013;2306. doi: 10.1056/NEJMoa1503780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1503780</ArticleId><ArticleId IdType="pubmed">25882510</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal M., Demchuk A.M., Menon B.K., Eesa M., Rempel J.L., Thornton J., Roy D., Jovin T.G., Willinsky R.A., Sapkota B.L., et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 2015;372:1019&#x2013;1030. doi: 10.1056/NEJMoa1414905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414905</ArticleId><ArticleId IdType="pubmed">25671798</ArticleId></ArticleIdList></Reference><Reference><Citation>Radad K., Moldzio R., Al-Shraim M., Kranner B., Krewenka C., Rausch W.D. Recent advances in autophagy-based neuroprotection. Expert Rev. Neurother. 2015;15:195&#x2013;205. doi: 10.1586/14737175.2015.1002087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.2015.1002087</ArticleId><ArticleId IdType="pubmed">25614954</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y., Yong Y., Yang G., Ding H., Fan Z., Tang Y., Luo J., Ke Z.J. Autophagy alleviates neurodegeneration caused by mild impairment of oxidative metabolism. J. Neurochem. 2013;126:805&#x2013;818. doi: 10.1111/jnc.12268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12268</ArticleId><ArticleId IdType="pmc">PMC3759557</ArticleId><ArticleId IdType="pubmed">23586593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S.K. Modulation of autophagy for neuroprotection and functional recovery in traumatic spinal cord injury. Neural Regen. Res. 2020;15:1601&#x2013;1612. doi: 10.4103/1673-5374.276322.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.276322</ArticleId><ArticleId IdType="pmc">PMC7437603</ArticleId><ArticleId IdType="pubmed">32209759</ArticleId></ArticleIdList></Reference><Reference><Citation>Doeppner T.R., Coman C., Burdusel D., Ancuta D.L., Brockmeier U., Pirici D.N., Yaoyun K., Hermann D.M., Popa-Wagner A. Long-term treatment with chloroquine increases lifespan in middle-aged male mice possibly via autophagy modulation, proteasome inhibition and glycogen metabolism. Aging. 2022;14:4195&#x2013;4210. doi: 10.18632/aging.204069.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.204069</ArticleId><ArticleId IdType="pmc">PMC9186778</ArticleId><ArticleId IdType="pubmed">35609021</ArticleId></ArticleIdList></Reference><Reference><Citation>Filfan M., Olaru A., Udristoiu I., Margaritescu C., Petcu E., Hermann D.M., Popa-Wagner A. Long-term treatment with spermidine increases health span of middle-aged Sprague-Dawley male rats. Geroscience. 2020;42:937&#x2013;949. doi: 10.1007/s11357-020-00173-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-020-00173-5</ArticleId><ArticleId IdType="pmc">PMC7287009</ArticleId><ArticleId IdType="pubmed">32285289</ArticleId></ArticleIdList></Reference><Reference><Citation>Krakauer T., Buckley M. Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock. Toxins. 2012;4:718&#x2013;728. doi: 10.3390/toxins4090718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins4090718</ArticleId><ArticleId IdType="pmc">PMC3475225</ArticleId><ArticleId IdType="pubmed">23105977</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran C.M., Mukherjee S., Ye L., Frederick D.W., Kissig M., Davis J.G., Lamming D.W., Seale P., Baur J.A. Rapamycin Blocks Induction of the Thermogenic Program in White Adipose Tissue. Diabetes. 2016;65:927&#x2013;941. doi: 10.2337/db15-0502.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db15-0502</ArticleId><ArticleId IdType="pmc">PMC4806661</ArticleId><ArticleId IdType="pubmed">26858361</ArticleId></ArticleIdList></Reference><Reference><Citation>Omileke D., Pepperall D., Bothwell S.W., Mackovski N., Azarpeykan S., Beard D.J., Coupland K., Patabendige A., Spratt N.J. Ultra-Short Duration Hypothermia Prevents Intracranial Pressure Elevation Following Ischaemic Stroke in Rats. Front. Neurol. 2021;12:684353. doi: 10.3389/fneur.2021.684353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.684353</ArticleId><ArticleId IdType="pmc">PMC8488292</ArticleId><ArticleId IdType="pubmed">34616350</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J., Van Broeckhoven C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum. Mol. Genet. 2013;22:R77&#x2013;R87. doi: 10.1093/hmg/ddt349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt349</ArticleId><ArticleId IdType="pmc">PMC3782069</ArticleId><ArticleId IdType="pubmed">23900071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Cleveland D.W. Rethinking ALS: The FUS about TDP-43. Cell. 2009;136:1001&#x2013;1004. doi: 10.1016/j.cell.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.03.006</ArticleId><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.C., Albuquerque C.P., Han J.S., Lagier-Tourenne C., Tokunaga S., Zhou H., Cleveland D.W. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl. Acad. Sci. USA. 2010;107:13318&#x2013;13323. doi: 10.1073/pnas.1008227107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesiridis G.S., Lee V.M., Trojanowski J.Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009;18:R156&#x2013;R162. doi: 10.1093/hmg/ddp303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp303</ArticleId><ArticleId IdType="pmc">PMC2758707</ArticleId><ArticleId IdType="pubmed">19808791</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Kaneko K., Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J. Biol. Chem. 2013;288:3641&#x2013;3654. doi: 10.1074/jbc.M112.433615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433615</ArticleId><ArticleId IdType="pmc">PMC3561582</ArticleId><ArticleId IdType="pubmed">23235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada S.J., Skibinski G., Korb E., Rao E.J., Wu J.Y., Finkbeiner S. Cytoplasmic Mislocalization of TDP-43 Is Toxic to Neurons and Enhanced by a Mutation Associated with Familial Amyotrophic Lateral Sclerosis. J. Neurosci. 2010;30:639&#x2013;649. doi: 10.1523/JNEUROSCI.4988-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Deng J., Dong J., Liu J., Bigio E.H., Mesulam M., Wang T., Sun L., Wang L., Lee A.Y., et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15:e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa M., Kakita A., Igarashi H., Takahashi T., Kawamura K., Takahashi H., Nakada T., Nishizawa M., Shimohata T. Biochemical and histopathological alterations in TAR DNA-binding protein-43 after acute ischemic stroke in rats. J. Neurochem. 2011;116:957&#x2013;965. doi: 10.1111/j.1471-4159.2010.06860.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06860.x</ArticleId><ArticleId IdType="pubmed">20557425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.B., Lee V.M., Trojanowski J.Q., Neumann M. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol. 2008;115:305&#x2013;311. doi: 10.1007/s00401-007-0331-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0331-5</ArticleId><ArticleId IdType="pubmed">18087705</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A., Majumder S., Deng J.J., Bai Y., Thornton F.B., Oddo S. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J. Biol. Chem. 2009;284:27416&#x2013;27424. doi: 10.1074/jbc.M109.031278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.031278</ArticleId><ArticleId IdType="pmc">PMC2785671</ArticleId><ArticleId IdType="pubmed">19651785</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter E.L., Vance C., Nishimura A.L., Lee Y.B., Chen H.J., Urwin H., Sardone V., Mitchell J.C., Rogelj B., Rubinsztein D.C., et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J. Cell Sci. 2014;127:1263&#x2013;1278. doi: 10.1242/jcs.140087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.140087</ArticleId><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansel G., Ramos D.B., Delgado C.A., Souza D.G., Almeida R.F., Portela L.V., Quincozes-Santos A., Souza D.O. The potential therapeutic effect of guanosine after cortical focal ischemia in rats. PLoS ONE. 2014;9:e90693. doi: 10.1371/journal.pone.0090693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090693</ArticleId><ArticleId IdType="pmc">PMC3938812</ArticleId><ArticleId IdType="pubmed">24587409</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.F., Lin S.Z., Chiang Y.H., Morales M., Chou J., Lein P., Chen H.L., Hoffer B.J., Wang Y. Intravenous administration of bone morphogenetic protein-7 after ischemia improves motor function in stroke rats. Stroke. 2003;34:558&#x2013;564. doi: 10.1161/01.STR.0000051507.64423.00.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000051507.64423.00</ArticleId><ArticleId IdType="pubmed">12574575</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomac A.C., Agulnick A.D., Haughey N., Chang C.F., Zhang Y., Backman C., Morales M., Mattson M.P., Wang Y., Westphal H., et al. Effects of cerebral ischemia in mice deficient in Persephin. Proc. Natl. Acad. Sci. USA. 2002;99:9521&#x2013;9526. doi: 10.1073/pnas.152535899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.152535899</ArticleId><ArticleId IdType="pmc">PMC123173</ArticleId><ArticleId IdType="pubmed">12093930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.F., Morales M., Chou J., Chen H.L., Hoffer B., Wang Y. Bone morphogenetic proteins are involved in fetal kidney tissue transplantation-induced neuroprotection in stroke rats. Neuropharmacology. 2002;43:418&#x2013;426. doi: 10.1016/S0028-3908(02)00092-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(02)00092-8</ArticleId><ArticleId IdType="pubmed">12243771</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.F., Niu K.C., Hoffer B.J., Wang Y., Borlongan C.V. Hyperbaric oxygen therapy for treatment of postischemic stroke in adult rats. Exp. Neurol. 2000;166:298&#x2013;306. doi: 10.1006/exnr.2000.7506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2000.7506</ArticleId><ArticleId IdType="pubmed">11085895</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Shoyaib A., Archie S.R., Karamyan V.T. Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? Pharm. Res. 2019;37:12. doi: 10.1007/s11095-019-2745-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-019-2745-x</ArticleId><ArticleId IdType="pmc">PMC7412579</ArticleId><ArticleId IdType="pubmed">31873819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima M., Taguchi A., Tsuda H., Sato Y., Yamahara K., Harada-Shiba M., Miyazato M., Ikeda T., Iida H., Tsuji M. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev. 2015;37:376&#x2013;386. doi: 10.1016/j.braindev.2014.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.braindev.2014.06.010</ArticleId><ArticleId IdType="pubmed">25034178</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodrum C., Nobil A., Dabora S.L. Comparison of three rapamycin dosing schedules in A/J Tsc2+/&#x2212; mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J. Transl. Med. 2010;8:14. doi: 10.1186/1479-5876-8-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-8-14</ArticleId><ArticleId IdType="pmc">PMC2834646</ArticleId><ArticleId IdType="pubmed">20146790</ArticleId></ArticleIdList></Reference><Reference><Citation>Isayama K., Pitts L.H., Nishimura M.C. Evaluation of 2,3,5-triphenyltetrazolium chloride staining to delineate rat brain infarcts. Stroke. 1991;22:1394&#x2013;1398. doi: 10.1161/01.STR.22.11.1394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.22.11.1394</ArticleId><ArticleId IdType="pubmed">1721247</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlongan C.V., Cahill D.W., Sanberg P.R. Locomotor and passive avoidance deficits following occlusion of the middle cerebral artery. Physiol. Behav. 1995;58:909&#x2013;917. doi: 10.1016/0031-9384(95)00103-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0031-9384(95)00103-P</ArticleId><ArticleId IdType="pubmed">8577887</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlongan C.V., Hida H., Nishino H. Early assessment of motor dysfunctions aids in successful occlusion of the middle cerebral artery. Neuroreport. 1998;9:3615&#x2013;3621. doi: 10.1097/00001756-199811160-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199811160-00012</ArticleId><ArticleId IdType="pubmed">9858369</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Kuo C.C., Shen H., Chou J., Greig N.H., Hoffer B.J., Wang Y. Delayed treatment with a p53 inhibitor enhances recovery in stroke brain. Ann. Neurol. 2009;65:520&#x2013;530. doi: 10.1002/ana.21592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21592</ArticleId><ArticleId IdType="pmc">PMC2690614</ArticleId><ArticleId IdType="pubmed">19475672</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M.J., Igaz L.M., Wong M.M., Kwong L.K., Trojanowski J.Q., Lee V.M. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008;283:13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>